1 unchanged sentence
Rule 10b5-1 trading arrangements
−Removed: During the three months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
+Added: During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Reference is made to the Index to Exhibits included herein.
INDEX TO EXHIBITS
−Removed: 2.1 Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC.
−Removed: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)
−Removed: 2.2 Agreement and Plan of Merger, dated as of August 3, 2022, among ChemoCentryx, Inc., Amgen Inc.
−Removed: and Carnation Merger Sub, Inc.
−Removed: (Filed as an exhibit to Form 8-K on August 4, 2022 and incorporated herein by reference.)
−Removed: 2.3 Transaction Agreement, dated as of December 11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc.
−Removed: (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)
−Removed: 2.4 Appendix 3 to the Rule 2.7 Announcement, dated as of December 12, 2022 (Conditions Appendix).
−Removed: (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)
3.1 Restated Certificate of Incorporation of Amgen Inc.
42 unchanged sentences
(Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)
−Removed: 4.21 Officer’s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Company’s 2.000% Senior Notes due 2026.
−Removed: (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)
4.21 Officer’s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Company’s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.
20 unchanged sentences
(Filed as an exhibit to Form 10-K for the year ended December 31, 2025 on February 13, 2026 and incorporated herein by reference.)
+Added: 4.32 Officer’s Certificate of the Company, dated as of February 19, 2026, including forms of the Company’s 4.200% Senior Notes due 2031, 4.850% Senior Notes due 2036, 5.500% Senior Notes due 2046 and 5.650% Senior Notes due 2056.
+Added: (Filed as an exhibit to Form 8-K on February 19, 2026 and incorporated herein by reference.)
10.1+ Amgen Inc.
89 unchanged sentences
and BeOne Medicines I GmbH and BeOne Medicines Ltd.
+Added: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2025 on November 5, 2025 and incorporated herein by reference.)
+Added: 10.19.5 Letter Agreement, dated October 1, 2025, by and between Amgen Inc.
+Added: and BeOne Medicines I GmbH and BeOne Medicines Ltd.
+Added: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2025 on February 13, 2026 and incorporated herein by reference.)
+Added: 10.19.6 Third Amendment to Collaboration Agreement, dated October 31, 2025, by and among Amgen Inc., BeOne Medicines I GmbH, and BeOne Medicines Ltd.
+Added: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2025 on February 13, 2026 and incorporated herein by reference.)
+Added: 10.19.7 F ourth Amendment to Collaboration Agreement, dated November 11, 2025, by and among Amgen Inc., BeOne Medicines I GmbH, and BeOne Medicines Ltd.
+Added: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2025 on February 13, 2026 and incorporated herein by reference.)
10.20 Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd.
35 unchanged sentences
and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2025 on August 5, 2025 and incorporated herein by reference.)
−Removed: 10.23 License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc.
−Removed: and Kyowa Kirin Co., Ltd.
−Removed: (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential).
−Removed: (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)
19.1 Amgen Inc.
23 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: November 4, 2025 By:
+Added: April 30, 2026 By:
/ S / PETER H.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.